Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing…
DURHAM, NC / ACCESSWIRE / May 15, 2024 / The Glioblastoma Foundation announced today the establishment of a pioneering Genomic…
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…
STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops…
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting…
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic…
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data…
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to…
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…